Eli Lilly Correlations
| LLY Stock | 38.40 1.40 3.78% |
The current 90-days correlation between Eli Lilly CDR and Amazon CDR is -0.1 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Eli Lilly Correlation With Market
Good diversification
The correlation between Eli Lilly CDR and DJI is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Eli Lilly CDR and DJI in the same portfolio, assuming nothing else is changed.
Eli |
The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly CDR to buy it.
Moving against Eli Stock
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Eli Stock performing well and Eli Lilly Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eli Lilly's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NVDA | 1.66 | (0.15) | 0.00 | (0.19) | 0.00 | 2.90 | 9.47 | |||
| NVDA | 1.66 | (0.15) | 0.00 | (0.20) | 0.00 | 2.90 | 9.47 | |||
| GOOG | 1.34 | 0.22 | 0.10 | 2.65 | 1.25 | 3.00 | 9.38 | |||
| AAPL | 0.79 | 0.02 | (0.04) | 0.15 | 0.92 | 2.18 | 5.41 | |||
| AAPL | 0.79 | 0.02 | (0.05) | 0.15 | 0.92 | 2.18 | 5.41 | |||
| GOOG | 1.34 | 0.22 | 0.10 | 2.62 | 1.25 | 3.00 | 9.38 | |||
| NFLX | 1.41 | (0.46) | 0.00 | (1.41) | 0.00 | 1.80 | 8.14 | |||
| MSFT | 1.33 | (0.41) | 0.00 | (0.78) | 0.00 | 1.82 | 13.66 | |||
| MSFT | 1.33 | (0.41) | 0.00 | (0.81) | 0.00 | 1.81 | 13.66 | |||
| AMZN | 1.32 | (0.28) | 0.00 | (1.14) | 0.00 | 2.50 | 7.66 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eli Lilly without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Eli Lilly Corporate Management
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diogo Rau | EVP Officer | Profile | |
| Gordon Brooks | Controller VP | Profile | |
| Jacob Naarden | Executive Oncology | Profile | |
| Donald Zakrowski | Senior Officer | Profile | |
| Eric Dozier | Executive Officer | Profile | |
| Jeffrey Simmons | Senior Health | Profile |